How should we use anti-CTLA-4 antibodies?

被引：7
|
作者：
Marabelle, Aurelien [1 ,2 ]
Eggermont, Alexander [1 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, F-94805 Villejuif, France
[2] INSERM, U1015, F-94805 Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷 / 17期
关键词：
REGULATORY T-CELLS; METASTATIC MELANOMA; IPILIMUMAB;
D O I：
10.1016/j.ejca.2015.09.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2686 / 2688
页数：3
相关论文
共 50 条
  • [21] Potent inhibition of CTLA-4 expression by an anti-CTLA-4 ribozyme
    Cepero, E
    Hnatyszyn, HJ
    Kraus, G
    Lichtenheld, MG
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (03) : 838 - 843
  • [22] Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
    Marthey, L.
    Mateus, C.
    Mussini, C.
    Nachury, M.
    Nancey, S.
    Grange, F.
    Zallot, C.
    Peyrin-Biroulet, L.
    Rahier, J. F.
    de Beauregard, M. Bourdier
    Mortier, L.
    Coutzac, C.
    Soularue, E.
    Lanoy, E.
    Kapel, N.
    Planchard, D.
    Chaput, N.
    Robert, C.
    Carbonnel, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (04): : 395 - 401
  • [23] Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
    Sato, Yosuke
    Casson, Cierra N.
    Matsuda, Atsushi
    Kim, James, I
    Shi, Judy Qiuju
    Iwasaki, Shinji
    Chen, Susan
    Modrell, Brett
    Chan, Chingkit
    Tavares, Daniel
    Austen, Douglas
    Ida, Koh
    Tayber, Olga
    Hein, Pyae
    Comeau, Robert
    Lin, Yafang
    Shaw, Michael H.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (10) : 2421 - 2431
  • [24] Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
    Yosuke Sato
    Cierra N. Casson
    Atsushi Matsuda
    James I. Kim
    Judy Qiuju Shi
    Shinji Iwasaki
    Susan Chen
    Brett Modrell
    Chingkit Chan
    Daniel Tavares
    Douglas Austen
    Koh Ida
    Olga Tayber
    Pyae Hein
    Robert Comeau
    Yafang Lin
    Michael H. Shaw
    Cancer Immunology, Immunotherapy, 2022, 71 : 2421 - 2431
  • [25] Inhibition of EZH2 improves the anti-tumor efficacy of anti-CTLA-4 antibodies
    Bui-Xuan, Philomene
    Ali, Francesca
    M S-MEDECINE SCIENCES, 2019, 35 (04): : 381 - 382
  • [26] Screening and antitumor effect of an anti-CTLA-4 nanobody
    Wan, Ruirong
    Liu, Aiqun
    Hou, Xiaoqiong
    Lai, Zongqiang
    Li, Jieping
    Yang, Nuo
    Tan, Juntao
    Mo, Fengzhen
    Hu, Zixi
    Yang, Xiaomei
    Zhao, Yongxiang
    Lu, Xiaoling
    ONCOLOGY REPORTS, 2018, 39 (02) : 511 - 518
  • [27] Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma
    Eggermont, Alexander M. M.
    Testori, Alessandro
    Maio, Michele
    Robert, Caroline
    SEMINARS IN ONCOLOGY, 2010, 37 (05) : 455 - 459
  • [28] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [29] Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
    Ribas, Antoni
    SEMINARS IN ONCOLOGY, 2010, 37 (05) : 450 - 454
  • [30] Anti-CTLA-4 human scFv antibodies prevent T-cell activation in transplantation
    Pistillo, MP
    Tazzari, PL
    Stirpe, F
    Bolognesi, A
    Polito, L
    Capanni, P
    Pioli, C
    Gatta, L
    Ubaldi, V
    Doria, G
    Conte, R
    Ferrara, GB
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 285 - 287
12345